Chiang Ling Li's practice has focused on China IP and pharmaceutical law since 1994. She has been in the forefront of the law, leading successful litigation involving patents, trade secrets, copyright, unfair competition, 3-D marks and well-known marks, as well as successfully pursuing criminal enforcement of IP infringement in China.
Chiang works closely with industry organizations lobbying for legal reforms, including those concerning patent linkage and data exclusivity, and has been appointed an arbitrator by CIETAC, HKIAC, ADNDRC, and the WIPO Arbitration and Mediation Center.
Chiang is author of China Executive Report: Intellectual Property, the China IP chapters of LexisNexis's Intellectual Property Rights, the "Anticounterfeiting and Enforcement" chapter in China's Participation in the WTO, and the China chapters in PLC Cross-border Life Sciences (2007-2012 editions), Trade Secrets Throughout the World Treatise, Patents Throughout the World, and Designs and Utility Models Throughout the World. She is also author of many articles on China IP and pharmaceutical law and practice.
Chiang was among the "A-List" of the top 100 lawyers for China (China Business Law Journal). She is also a PLC recommended lawyer in all three categories of life sciences: intellectual property, corporate and commercial (China), and corporate and commercial. Chiang also has been recognized by The International Who's Who of Life Sciences Lawyers, World Trademark Review (WTR 1000), Chambers Asia-Pacific and Chambers Global, The International Who's Who of Life Sciences Lawyers, The International Who's Who of Business Lawyers, IAM 1000 — The World's Leading Patent Professionals, WTR 1000 — The World's Leading Trademark Professionals, and IAM Licensing 250: The World's Leading Patent and Technology Licensing Practitioners.
Areas of expertise
- Intellectual property
- Global disputes
- Healthcare & life sciences
- Abuse of patent litigation in a Chinese Court – Successfully acting for a European heavy machinery company on an abuse of patent case including large damage awards. Defendant was found by the Suzhou Intermediate People’s Court to have patented other companies’ technology and Chinese national standards. Defendant appealed and the case is pending.
- China life sciences regulatory due diligence in an acquisition of a US pharmaceutical company – Advising a Japanese multinational company on regulatory due diligence, negotiation, contract drafting and post signing and post-closing regulatory work relating to multiple therapeutic candidates, including those for community-acquired bacterial pneumonia, overactive bladder, and advanced prostate cancer.
- Copyright litigation to fight trademark piracy – Acting for a European/US based multinational sporting accessory products in the highest court in China (the Supreme People’s Court) using copyright in around 50 proceedings to take back pirated marks, which the pre-empted pirate derailed the multinational’s China expansion plan. One case in the group of cases is still pending at the Beijing High People’s Court.
- Patent non-infringement declaratory judgement – Acting for a European heavy machinery multinational company in the Intellectual Property Tribunal of the highest court in China (the Supreme People’s Court) to stop patent hijackers to raid customers of legitimate technology owners. The case has been codified in the Chinese Supreme People’s Court Judicial Interpretation (which has the force of law in China), promulgated on 16 November 2020.
- Won trademark dilution case and obtained well-known mark status in the education industry – Successfully acting for one of the world's largest non-profit education testing organizations on a trademark dilution case. The China's State Intellectual Property Office has selected the case as a guiding case and published guidance notes focusing on the well-known mark award.
*included matters handled prior to joining Tiang & Partners.